Showing 1 - 10 of 10
We propose that innovative originality (InnOrig) is a valuable organizational resource, and that owing to limited investor attention and skepticism of complexity, firms with greater InnOrig are undervalued. We find that firms' InnOrig strongly predicts higher, more persistent, and less volatile...
Persistent link: https://www.econbiz.de/10012955455
Firms can become less innovative following a sudden “inflow” of cash. Specifically, multinational firms that were eligible to repatriate (and indeed repatriated) cash to the U.S. under the American Jobs Creation Act generate less valuable patents than otherwise similar firms. They also...
Persistent link: https://www.econbiz.de/10012902017
Persistent link: https://www.econbiz.de/10011927144
Persistent link: https://www.econbiz.de/10011669408
We propose that innovative originality is a valuable organizational resource, and that owing to limited investor attention and skepticism of complexity, greater innovative originality may be undervalued. We find that firms' innovative originality strongly predicts higher, more persistent, and...
Persistent link: https://www.econbiz.de/10012857235
Persistent link: https://www.econbiz.de/10012437369
These are the slides for the paper “Innovative Originality, Profitability, And Stock Returns.” The abstract of this paper is the following: We propose that innovative originality is a valuable organizational resource and that owing to limited investor attention and skepticism of complexity,...
Persistent link: https://www.econbiz.de/10012917506
We propose that innovative originality (InnOrig) is a valuable organizational resource, and that owing to limited investor attention and skepticism of complexity, firms with greater InnOrig are undervalued. We find that firms' InnOrig strongly predicts higher, more persistent, and less volatile...
Persistent link: https://www.econbiz.de/10012455249
We analyze, theoretically and empirically, how salience affects the market reaction to innovation announcements. Hypothesizing that equity market investors pay more attention to more salient announcements, we develop a dynamic model with limited investor attention of patent grant and FDA drug...
Persistent link: https://www.econbiz.de/10014352443
We analyze, theoretically and empirically, the implications of salience on innovation announcements in the biopharmaceutical industry. We hypothesize that equity market investors are more likely to pay attention to an innovation announcement that is more salient: thus, investors pay more...
Persistent link: https://www.econbiz.de/10014352748